Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.

Abstract: An improved device and system for facilitating polymerase chain reaction including a light source, detector, waveguide, and filters that occupy minimal space and facilitate detection of stationary samples, reduced sample read time, and simultaneous reading of multiple light wavelengths.

Abstract: The present application provides for compositions comprising high concentrations of acid a-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.

Abstract: An improved device and system for facilitating polymerase chain reaction including a light source, detector, waveguide, and filters that occupy minimal space and facilitate detection of stationary samples, reduced sample read time, and simultaneous reading of multiple light wavelengths.

Abstract: Examples of techniques for queuing an input/output (I/O) operation in a multi-queue are disclosed. In one example implementation according to aspects of the present disclosure, an example computer-implemented method may include receiving, by a general purpose processor, the I/O operation. The method may further include transmitting, by the general purpose processor, the I/O operation to a system assist processor. The method may further include transmitting, by the system assist processor, the I/O operation to an I/O channel for execution by the I/O channel, wherein transmitting the I/O operation to the I/O channel comprises queuing the I/O operation in the multi-queue. The method may further include executing, by the I/O channel, the I/O operation.

Abstract: Examples of techniques for processing I/O operations in a channel are disclosed. In one example implementation according to aspects of the present disclosure, a computer-implemented method may include: copying, by a system assist processor, a subchannel of the channel into a lower portion of a channel communication area responsive to receiving the I/O operation; copying, by the system assist processor, channel program information from a designated starting location in a customer memory into a control block; building, by the system assist processor, a starting channel communication area into a top portion of the control block; queuing, by the system assist processor, the control block to a queue for the channel; processing, by the channel, the I/O operation responsive to retrieving the control block from the queue.

Abstract: The presently disclosed subject matter relates to methods of determining whether a canine animal is predisposed to being overweight in adulthood, and methods of preventing a canine animal from being overweight in adulthood. The present application also provides a diet or a dietary regime for use in preventing a canine animal from being overweight in adulthood.

Abstract: Examples of techniques for processing I/O operations in a channel are disclosed. In one example implementation according to aspects of the present disclosure, a computer-implemented method may include: copying, by a system assist processor, a subchannel of the channel into a lower portion of a channel communication area responsive to receiving the I/O operation; copying, by the system assist processor, channel program information from a designated starting location in a customer memory into a control block; building, by the system assist processor, a starting channel communication area into a top portion of the control block; queuing, by the system assist processor, the control block to a queue for the channel; processing, by the channel, the I/O operation responsive to retrieving the control block from the queue.

Abstract: The present invention relates to a metal leach and recovery process. The process involves subjecting a metal bearing material to a reactive process by combining said metal bearing material with a leaching agent to liberate at least one metal value and forming a first aqueous leach pulp. This first aqueous leach pulp is subjected to a solid liquid separation step thereby providing a first clarified aqueous leach solution and a second aqueous leach pulp. The first clarified aqueous leach solution is then subjected to solvent extraction thereby obtaining the first aqueous raffinate. The second aqueous leach pulp is subjected to at least two further solid liquid separation steps of which some or all are in a counter current decantation (CCD) arrangement.

Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: Antibodies, and antibody pairs, that bind and specifically detection pre-Haptoglobin-2, and methods for their use, are provided.

Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.

Abstract: An improved device and system for facilitating polymerase chain reaction including a light source, detector, waveguide, and filters that occupy minimal space and facilitate detection of stationary samples, reduced sample read time, and simultaneous reading of multiple light wavelengths.

Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.